Why it matters
IDERHA is part of the Europe Beating Cancer Plan. It will link and analyse, with artificial intelligence and machine learning, diverse human health data to improve early detection of lung cancer and the quality of life for individuals with experience with lung cancer. IDERHA has the task to demonstrate that this data-driven approach has an added value for patients where clinical co-decision making and personalized disease management is possible. IDERHA is building one of the first pan-European health data spaces and is constantly aligned with the implementation of the proposal European Health Data Space (EHDS) in the following years. To enable patients and healthcare providers to benefit from novel health solutions, IDERHA seeks to accelerate policy development. Thereby, IDERHA aids regulatory approval and Health Technology Assessments (HTA).
What ECPC does
The patient voice will be a major part of the development of consensus on policy recommendations around ethical and legal governance of heterogeneous health data access and sharing to enable multi-stakeholder research, and criteria for the evaluation of research derived from heterogeneous health data for regulatory and Health Technology Assessment (HTA) for decision-making. Included in the consortium are major actors in previous and present EU Cancer Actions and Initiatives to ensure continuity and congruence with past and current work. The Patient Advisory Board and Patient Engagement will provide feedback and co-designs all aspects of the patient journey for all activities that involve patients with a strong emphasis on tools that empower patient for consenting, disease self-management and joint decision-making with the clinician and the patient.
This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112135.